Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 448
- Registration Number
- NCT06699576
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Target Recruit Count
- 29
- Registration Number
- NCT06470633
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT06404463
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 36
- Registration Number
- NCT06309732
- Locations
- 🇬🇧
Barts and the London NHS Trust, London, United Kingdom
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 85
- Registration Number
- NCT06291064
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- University of Bern
- Target Recruit Count
- 28
- Registration Number
- NCT06227065
- Locations
- 🇨🇭
Roland Seiler, Biel, Switzerland
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Target Recruit Count
- 24
- Registration Number
- NCT06121570
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath